Neuroprotective effects of sulforaphane after contusive spinal cord injury.
Level 5 - mechanism / opinion, no new human data
Animal research (rat contusive spinal cord injury model)
PubMed 22853439 · doi:10.1089/neu.2012.2474
What was done
Researchers administered systemic sulforaphane (SF) at doses of 10 or 50 mg/kg at 10 minutes and 72 hours following contusion spinal cord injury (SCI) in a rat model. Outcomes evaluated included phase 2 antioxidant response upregulation, spinal cord inflammatory cytokine mRNA expression (e.g., MMP-9), urinary macrophage migration inhibitory factor (MIF) tautomerase activity, serotonergic axon counts caudal to the lesion, and hindlimb locomotor functional recovery.
What was found
Administration of 50 mg/kg SF produced acute and long-term neuroprotective effects, including upregulation of phase 2 antioxidant pathways at the injury site, decreased mRNA levels of inflammatory cytokines (including MMP-9), inactivation of urinary MIF tautomerase activity, increased serotonergic axon preservation caudal to the lesion, and improved hindlimb locomotor function. The abstract did not report specific numerical values, effect sizes, or statistical figures.
Why it matters
The findings suggest that targeting both the Nrf2 antioxidant pathway and NF-κB/MIF-mediated inflammatory cascades with sulforaphane can mitigate secondary damage and promote functional recovery after mechanical spinal cord trauma.
Limits
The study was conducted entirely in a rodent model and cannot be directly translated to human clinical outcomes. The abstract omits sample sizes (n), exact quantitative metrics, and statistical measures of variance or significance. Only two discrete dosing time points were tested.
Cited by
- supports Sulforaphane demonstrates protective effects in preclinical models of traumatic brain injury and spinal cord injury.